Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 66,900 shares, the days-to-cover ratio is currently 0.8 days.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on MNPR shares. Piper Sandler assumed coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They issued an "overweight" rating and a $72.00 target price on the stock. HC Wainwright raised their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd.
Check Out Our Latest Report on Monopar Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of MNPR. Janus Henderson Group PLC bought a new position in Monopar Therapeutics in the 4th quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics during the 4th quarter worth about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics in the 4th quarter valued at about $2,861,000. 1.83% of the stock is owned by institutional investors and hedge funds.
Monopar Therapeutics Stock Up 0.6 %
NASDAQ:MNPR traded up $0.20 on Tuesday, reaching $34.43. The stock had a trading volume of 17,565 shares, compared to its average volume of 358,996. The company has a market capitalization of $210.09 million, a P/E ratio of -17.48 and a beta of 1.18. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The stock has a fifty day moving average price of $35.98 and a 200-day moving average price of $21.76.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
